Abstract
Objectives To provide data on the immune response to COVID-19 vaccines in people living with HIV (PWH), MVC-COV1901, a recombinant protein vaccine containing S-2P protein adjuvanted with CpG 1018 and aluminium hydroxide, was assessed.
Methods A total of 57 PWH of ≥ 20 years of age who are on stable antiretroviral therapy and with CD4+ T cell ≥ 350 cells/mm3 and HIV viral load < 103 copies/ml were compared with 882 HIV-negative participants. Participants received 2 doses of MVC-COV1901 28 days apart. Safety and the immunogenicity were evaluated.
Results No vaccine-related serious adverse events (SAEs) were recorded. Seroconversion rates (SCRs) of 100% and 99.8% were achieved in people living with HIV (PWH) and comparators, respectively, 28 days after second dose. The geometric mean titers (GMTs) (95% confidence interval [CI]) against wild type SARS-CoV-2 virus were 136.62 IU/mL (WHO Standardized International Unit) (95% CI 114.3-163.3) and 440.41 IU/mL (95% CI 421.3-460.4), for PWH and control groups, respectively, after adjusting for sex, age, BMI category, and comorbidity, and the adjusted GMT ratio of comparator/PWH was 3.22 (95% CI 2.6-4.1). A higher CD4/CD8 ratio was associated with a higher GMT (R=0.27, p=0.039).
Conclusions MVC-COV1901 has shown robust safety but weaker immunogenicity responses in PWH. As a result, a third dose or booster doses of MVC-COV1901 may be appropriate for PWH.
Competing Interest Statement
Chia En Lien, Josue Antonio Garcia Estrada and I-Chen Tai are employees of Medigen Vaccine Biologics (Taipei, Taiwan) and they received grants from Taiwan Centres for Disease Control, Ministry of Health and Welfare, during the conduct of the study. All other authors declare no competing interests.
Clinical Trial
NCT04695652
Funding Statement
The study was funded by Medigen Vaccine Biologics (study sponsor), the Taiwan Centers for Disease Control and Ministry of Health and Welfare.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial protocol and informed consent form were reviewed and approved by the ethics committees at the participating sites. The main institutional review board was Chang Gung Medical Foundation (Taoyuan, Taiwan), and other institutional review boards were the following institutes in Taiwan: National Taiwan University Hospital (Taipei), Taipei Veterans General Hospital (Taipei), Tri-Service General Hospital (Taipei), Taipei Medical University Hospital (Taipei), Taipei Municipal Wanfang Hospital (Taipei), Taoyuan General Hospital Ministry of Health and Welfare (Taoyuan), China Medical University Hospital (Taichung), Changhua Christian Hospital (Changhua County), National Cheng Kung University Hospital (Tainan), and Kaoshiung Medical University Chung-Ho Memorial Hospital (Kaoshiung). The trial was done in accordance with the principles of the Declaration of Helsinki and good clinical practice guidelines.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data sharing is not applicable to this Article, as it is an interim analysis of data from an ongoing study.
